Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Salpingo-Oophorectomy | Research article

Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary

Authors: Sijian Li, Tengyu Yang, Yang Xiang, Xiaoyan Li, Limeng Zhang, Shan Deng

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Malignant struma ovarii (MSO) is a unique type of ovarian malignancy that data on the survival outcome is limited and management strategy remains controversial due to its extreme rarity.

Methods

To investigate the clinical characteristics and treatment options in patients with MSO confined to the ovary, while also evaluating the recurrent-free survival (RFS) and overall survival (OS) rate in this population, a retrospective study was conducted. One hundred twenty-five cases of MSO confined to the ovary were enrolled and their clinical characteristics, treatment strategies, and results of follow-up were analyzed. OS and RFS were assessed by Kaplan-Meier analyses and Cox regression models.

Results

The most common pathological subtype in this cohort was papillary carcinoma (44.8%). Other reported subtypes, in order of prevalence, were follicular variant of papillary carcinoma, follicular carcinoma, and mixed follicular-papillary carcinoma. Surgical treatment options varied in this cohort that 8.0% of the patients received ovarian cystectomy, 33.6% underwent unilateral salpingo-oophorectomy (USO), 5.6% received bilateral salpingo-oophorectomy (BSO), 21.6% received total abdominal hysterectomy with BSO (TAH/BSO), and 17.6% were treated with debulking surgery; 20.0% of them received radioiodine therapy (RAI). Twenty-seven patients experienced recurrence with a median RFS of 14.0 years (95% confidence interval [CI], 9.5–18.5). The 5-year and 10-year recurrent rate were 27.1, 35.2%, respectively. Eight patients died during follow-up, with five attributed to MSO; the 5-year, 10-year, and 20-year OS rate was 95.3, 88.7 and 88.7%, respectively. However, the univariate and multivariate Cox regression showed no potential risk factor for RFS and OS.

Conclusion

Patients with MSO confined to the ovary had an excellent survival outcome, despite varied treatment strategies, and the recurrent rate was relatively high. We recommend USO as the preferred surgical option in this population since more aggressive surgery does not improve outcomes and the benefits of RAI are uncertain.

Available only for authorised users

Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol. 1993;12(4):333–43. https://doi.org/10.1097/00004347-199310000-00008.CrossRefPubMed

Yassa L, Sadow P, Marqusee E. Malignant struma ovarii. Nat Clin Pract Endocrinol Metab. 2008;4(8):469–72.CrossRef

Fujiwara S, Tsuyoshi H, Nishimura T, Takahashi N, Yoshida Y. Precise preoperative diagnosis of struma ovarii with pseudo-Meigs’ syndrome mimicking ovarian cancer with the combination of 131I scintigraphy and 18F–FDG PET: case report and review of the literature. J Ovarian Res. 2018;11(1):11. https://doi.org/10.1186/s13048-018-0383-2.CrossRefPubMedPubMedCentral

Gonzalez Aguilera B, Guerrero Vazquez R, Gros Herguido N, Sanchez Gallego F, Navarro GE. The lack of consensus in management of malignant struma ovarii. Gynecol Endocrinol. 2015;31(4):258–9. https://doi.org/10.3109/09513590.2014.995616.CrossRefPubMed

Hanby A, Walker C. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series - volume IV. Lyon: IARC Press. Breast Cancer Res. 2004; 6(3): 133.

Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: an unusual presentation. Thyroid. 2001;11(9):889–92. https://doi.org/10.1089/105072501316973163.CrossRefPubMed

Siegel MR, Wolsky RJ, Alvarez EA, Mengesha BM. Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature. Arch Gynecol Obstet. 2019;300(6):1693–707. https://doi.org/10.1007/s00404-019-05329-z.CrossRefPubMed

Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA. Malignant struma ovarii: a population-level analysis of a large series of 68 patients. Thyroid. 2015;25(2):211–5. https://doi.org/10.1089/thy.2014.0328.CrossRefPubMed

DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol. 2003;89(3):543–8. https://doi.org/10.1016/S0090-8258(03)00141-0.CrossRefPubMed

10.

Shrimali RK, Shaikh G, Reed NS. Malignant struma ovarii: the west of Scotland experience and review of literature with focus on postoperative management. J Med Imag Radiat Oncol. 2012;56(4):478–82. https://doi.org/10.1111/j.1754-9485.2012.02394.x.CrossRef

11.

McGill JF, Sturgeon C, Angelos P. Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation. Endocr Pract. 2009;15(2):167–73. https://doi.org/10.4158/EP.15.2.167.CrossRefPubMed

12.

Marti JL, Clark VE, Harper H, Chhieng DC, Sosa JA, Roman SA. Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: a series of 4 patients and a review of 53 reported cases. Thyroid. 2012;22(4):400–6. https://doi.org/10.1089/thy.2011.0162.CrossRefPubMed

13.

Jean S, Tanyi JL, Montone K, McGrath C, Lage-Alvarez MM, Chu CS. Papillary thyroid cancer arising in struma ovarii. J Obstet Gynaecol. 2012;32(3):222–6. https://doi.org/10.3109/01443615.2011.645921.CrossRefPubMed

14.

Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol. 2009;28(5):405–22. https://doi.org/10.1097/PGP.0b013e3181a27777.

15.

Li S, Yang T, Li X, Zhang L, Shi H, Cheng N, et al. FIGO stage IV and age over 55 years as prognostic predicators in patients with metastatic malignant Struma Ovarii. Front Oncol. 2020;10:584917. https://doi.org/10.3389/fonc.2020.584917.

16.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.

17.

Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ. Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol. 2010;29(3):212–27. https://doi.org/10.1097/PGP.0b013e3181bfb133.CrossRefPubMed

18.

Gunasekaran S, Kopecka E, Maung KH, England RJ. Struma ovarii and the thyroid surgeon. J Laryngol Otol. 2012;126(8):858–60. https://doi.org/10.1017/S0022215112000904.CrossRefPubMed

19.

O'Neill JP, Burns P, Kinsella J. Papillary type thyroid carcinoma in an ovarian struma. Ir J Med Sci. 2012;181(1):115–7. https://doi.org/10.1007/s11845-010-0467-5.CrossRefPubMed

20.

Griffiths AN, Jain B, Vine SJ. Papillary thyroid carcinoma of struma ovarii. J Obstet Gynaecol. 2004;24(1):92–3. https://doi.org/10.1080/01443610310001627209.CrossRefPubMed

21.

Kostoglou-Athanassiou I, Lekka-Katsouli I, Gogou L, Papagrigoriou L, Chatonides I, Kaldrymides P. Malignant struma ovarii: report of a case and review of the literature. Horm Res. 2002;58(1):34–8. https://doi.org/10.1159/000063215.CrossRefPubMed

22.

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les etudes des cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. https://doi.org/10.1002/cncr.24149.CrossRefPubMed

23.

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. https://doi.org/10.3322/caac.21559.CrossRefPubMed

24.

Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association stratification system. Thyroid. 2020;30(5):713–9. https://doi.org/10.1089/thy.2019.0688.

25.

Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid Cancer at high risk of recurrence. J Clin Endocrinol Metab. 2018;103(2):689–97. https://doi.org/10.1210/jc.2017-02255.CrossRefPubMed

26.

Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16(10):1019–23. https://doi.org/10.1089/thy.2006.16.1019.CrossRefPubMed

27.

Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612–8. https://doi.org/10.1097/AOG.0b013e318264f794.

28.

Yang Z, Flores J, Katz S, Nathan CA, Mehta V. Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid. 2017;27(7):944–52. https://doi.org/10.1089/thy.2016.0650.CrossRefPubMed

29.

Fujiwara S, Tsuyoshi H, Nishimura T, Takahashi N, Yoshida Y. Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of (131) I scintigraphy and (18) F-FDG PET: case report and review of the literature. J Ovarian Res. 2018;(1):11. https://doi.org/10.1186/s13048-018-0383-2.

30.

Shaco-Levy R, Peng RY, Snyder MJ, Osmond GW, Veras E, Bean SM, et al. Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior. Arch Pathol Lab Med. 2012;136(2):172–8. https://doi.org/10.5858/arpa.2011-0092-OA.

31.

van Velsen EFS, Visser WE, van den Berg SAA, Kam BLR, van Ginhoven TM, Massolt ET, et al. Longitudinal analysis of the effect of radioiodine therapy on ovarian Reserve in Females with differentiated thyroid Cancer. Thyroid. 2020;30(4):580–7. https://doi.org/10.1089/thy.2019.0504.

32.

Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid Cancer: a meta-analysis. Thyroid. 2017;27(5):651–60. https://doi.org/10.1089/thy.2016.0350.

33.

Coyne C, Nikiforov YE. RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol. 2010;21(2):144–7. https://doi.org/10.1007/s12022-009-9097-8.CrossRefPubMed

34.

Boutross-Tadross O, Saleh R, Asa SL. Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol. 2007;18(3):182–6. https://doi.org/10.1007/s12022-007-0022-8.CrossRefPubMed

35.

Poli R, Scatolini M, Grosso E, Maletta F, Gallo M, Liscia D, et al. Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. Endocrine. 2020;70(3):661. https://doi.org/10.1007/s12020-020-02514-y.

36.

Tan A, Stewart CJ, Garrett KL, Rye M, Cohen PA. Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in Struma Ovarii. Endocr Pathol. 2015;26(4):296–301. https://doi.org/10.1007/s12022-015-9394-3.CrossRefPubMed

37.

Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, et al. Genomic alterations in fatal forms of non-anaplastic thyroid Cancer: identification of MED12 and RBM10 as novel thyroid Cancer genes associated with tumor virulence. Clin Cancer Res. 2017;23(19):5970–80. https://doi.org/10.1158/1078-0432.CCR-17-1183.

38.

Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856–83. https://doi.org/10.1093/annonc/mdz400.

Title: Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary
Authors: Sijian Li
Tengyu Yang
Yang Xiang
Xiaoyan Li
Limeng Zhang
Shan Deng
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Salpingo-Oophorectomy
Radioiodine Therapy
Goiter
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08118-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan

Risk factors of breast cancer among patients in a tertiary care hospitals in Afghanistan: a case control study

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy

Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer